Clinical Trials

Leading the treatment of infectious conjunctivitis

The RUBY Trial evaluated the anti-viral safety and efficacy of OKG-0301.

Results demonstrated that OKG-0301 is safe, well-tolerated and accelerates viral clearance in a dose-responsive fashion.

OKG-0301 is a safe and effective antiviral

  • qPCR & CC-IFA demonstrate consistent, dose-responsive antiviral activity
  • AE profile (ocular & non-ocular) is uneventful
  • Ph2b planned with a fixed combination of OKG-0301 (antiviral) + Ocular Decongestant (Signs and Symptomns) + Antibiotic (antibacterial).
More information about clinical trial results can be found at clinicaltrials.gov
Learn More About the RUBY Trial

Latest News & Press

View All News
Press Release

Okogen, Inc., Announces Ophthalmology Industry Veteran Joshua Moriarty as New Chief Executive Officer

March 8, 2022
Read More
Press Release

Safe, Effective and Dose Responsive Anti-Viral Activity of OKG-0301 in Patients with Acute Adenoviral Conjunctivitis–Phase 2 Interim Analysis Results from RUBY Clinical Trial

April 29, 2021
Read More
Press Release

Okogen Initiates Phase 2 Clinical Trial (RUBY) of OKG-0301 in Patients

January 31, 2019
Read More

© 2023 Okogen, Inc. All Rights Reserved

United States

Okogen, Inc.
332 Encinitas Blvd. Suite 102
Encinitas, CA 92024, USA

Australia

Okogen Pty Ltd
Level 9, 31 Queen St
Melbourne, VIC 3000 AUS

Main Menu